Subsequent Event	3 Months Ended
Mar. 31, 2022
Subsequent Events
Subsequent Events	Note 15. Subsequent Event Acquisition of Cell&Co BioServices In April 2022, we completed the acquisition of Cell&Co BioServices in Clermont-Ferrand, France with additional operations in Pont-du-Château, France to further enhance our existing global temperature-controlled supply chain capabilities. Cell&Co BioServices is a bioservices business providing biorepository, kitting, and logistics services to the life sciences industry. The purchase consideration was €6.1 million ($6.7 million), comprised of upfront consideration of €3.2 million ($3.5 million) in cash, 15,152 shares of the Company’s common stock, and a potential earn-out of €2.5 million ($2.7 million) in cash based on achieving certain financial targets through March 31, 2025. Repurchase Program The Company purchased 600,000 shares of its common stock under the Repurchase Program during April 2022, at an average price of $24.16 per share, for an aggregate purchase price of $14.5 million. Year-to-date purchases through April 30, 2022, were 906,300 shares of common stock at an average price of $25.20 per share, for an aggregate purchase price of $22.8 million. Shares purchased under the Repurchase Program were returned to the status of authorized but unissued shares of common stock, were made using cash resources and are reported in the period based on the settlement date of the applicable repurchase.

Subsequent Event

3 Months Ended

Mar. 31, 2022

Note 15. Subsequent Event

Acquisition of Cell&Co BioServices

In April 2022, we completed the acquisition of Cell&Co BioServices in Clermont-Ferrand, France with additional operations in Pont-du-Château, France to further enhance our existing global temperature-controlled supply chain capabilities. Cell&Co BioServices is a bioservices business providing biorepository, kitting, and logistics services to the life sciences industry. The purchase consideration was €6.1 million ($6.7 million), comprised of upfront consideration of €3.2 million ($3.5 million) in cash, 15,152 shares of the Company’s common stock, and a potential earn-out of €2.5 million ($2.7 million) in cash based on achieving certain financial targets through March 31, 2025.

Repurchase Program

The Company purchased 600,000 shares of its common stock under the Repurchase Program during April 2022, at an average price of $24.16 per share, for an aggregate purchase price of $14.5 million. Year-to-date purchases through April 30, 2022, were 906,300 shares of common stock at an average price of $25.20 per share, for an aggregate purchase price of $22.8 million. Shares purchased under the Repurchase Program were returned to the status of authorized but unissued shares of common stock, were made using cash resources and are reported in the period based on the settlement date of the applicable repurchase.